Abbott (NYSE: ABT) announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received CE Mark in Europe for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE